JCR Pharmaceuticals Co., Ltd. announced that it has achieved the first research milestone criterion in a collaboration with Alexion, AstraZeneca Rare Disease ("Alexion") to develop an undisclosed initial therapeutic molecule that applies JCR's proprietary J-Brain Cargo®?, blood-brain barrier penetration technology, for the treatment of a neurodegenerative disease. The achievement of a predefined research milestone triggers a milestone payment to JCR. JCR recently strengthened its collaboration with Alexion to address unmet needs by initiating a second research collaboration in December 2023 to apply the same technology to oligonucleotide therapeutics.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
604 JPY | -2.42% | -3.82% | -48.46% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.46% | 509M | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion